Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - neoplasmi prostatiċi - terapija endokrinali - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - neoplasmi prostatiċi - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunoloġiċi għal suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. kontributur ewlieni ieħor għall-tifqigħa tal-ħanżir, skatole, jista 'jitnaqqas ukoll bħala effett indirett. mġieba aggressiva u sesswali (immuntar) huma wkoll imnaqqsa. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - aġenti antineoplastiċi oħra - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - neoplasmi prostatiċi - terapija endokrinali - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi pasteur - hepatitis b surface antigen, diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens pertussis toxoid filamentous haemagglutinin, poliovirus (inactivated) type 1 (mahoney) type 2 (mef-1) type 3 (saukett), haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines, bacterial and viral vaccines, combined - hexacima (dtap-ipv-hb-hib) huwa indikat għat-tilqim primarja u booster tat-trabi u toddlers minn sitt ġimgħat ta ' età kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u invażivi mard ikkawżat minn influwenza Ħemofillika tip b (hib). l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer animal health gmbh - imidakloprid, moksidektin - prodotti kontra l-parassiti, insettiċidi u repellenti - dogs; cats; ferrets - dogsfor klieb li qed isofru minn, jew huma f'riskju minn infezzjonijiet kawżati minn parassiti diversi:it-trattament u l-prevenzjoni tal-infestazzjoni mill-briegħed (ctenocephalides felis),trattament tal-qamel li jigdem (trichodectes canis),trattament ta ' infestazzjoni dudu tal-widna (otodectes cynotis), sarcoptic mange (ikkawżata minn sarcoptes scabiei var. canis), 'domodikosis (ikkawżata minn demodex canis),il-prevenzjoni tal-heartworm disease (l3 u l-larva l4 tad-dirofilaria immitis),trattament ta jiċċirkola microfilariae (dirofilaria immitis),il-kura ta' cutaneous dirofilariosis (adulti l-istadji tal-dirofilaria repens)il-prevenzjoni tal-ġilda dirofilariosis (larva l3 tal-dirofilaria repens),it-tnaqqis tal jiċċirkola microfilariae (dirofilaria repens),il-prevenzjoni tal-angiostrongylosis (larva l4 u l-adulti immaturi ta 'angiostrogylus vasorum),it-trattament ta' angiostrogylus vasorum u crenosoma vulpis,il-prevenzjoni tal-spirocercosis (spirocerca lupi),it-trattament tal-eucoleus (sin. capillaria) boehmi (adulti),il-kura ta 'l-għajn worm thelazia callipaeda (adulti),il-kura ta' infezzjonijiet bl-ħniex gastro-intestinali (larva l4, adulti immaturi u l-adulti tal-toxocara canis, ancylostoma caninum u uncinaria stenocephala, adulti tat-toxascaris leonina u trichuris vulpis). il-prodott jista 'jintuża bħala parti minn strateġija ta' trattament għal dermatite tal-allerġija tal-briegħed (fad). catsfor-qtates li jbatu minn, jew huma f'riskju minn infezzjonijiet kawżati minn parassiti diversi:it-trattament u l-prevenzjoni tal-infestazzjoni mill-briegħed (ctenocephalides felis),trattament ta 'infestazzjoni dudu tal-widna (otodectes cynotis),it-trattament tal-notoedric mange (notoedres cati),il-kura ta' l-lungworm eucoleus aerophilus (sin. capillaria aerophila) (adulti),il-prevenzjoni tal-lungworm-marda (l3/larva l4 ta'aelurostrongylus abstrusus),il-kura ta 'l-lungworm aelurostrongylus abstrusus (adulti),il-kura ta' l-għajn worm thelazia callipaeda (adulti),il-prevenzjoni tal-heartworm disease (l3 u l-larva l4 tad-dirofilaria immitis),trattament ta ' infezzjonijiet b'nematodi gastrointestinali (larva l4, adulti immaturi u l-adulti tal-toxocara cati u ancylostoma tubaeforme). il-prodott jista 'jintuża bħala parti minn strateġija ta' trattament għal dermatite tal-allerġija tal-briegħed (fad). ferretsfor l-inmsa li qed isofru minn, jew huma f'riskju minn infezzjonijiet kawżati minn parassiti diversi:it-trattament u l-prevenzjoni tal-infestazzjoni mill-briegħed (ctenocephalides felis),il-prevenzjoni tal-heartworm disease (l3 u l-larva l4 tad-dirofilaria immitis).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - streptococcus equi strain mutant tat-tħassir ħaj tw928 - immunoloġiċi għall-equidae - Żwiemel - għall-immunizzazzjoni taż-żwiemel kontra streptococcus equi biex tnaqqas is-sinjali kliniċi u l-okkorrenza tal-limfa-axxesi. il-bidu tal-immunità: il-bidu tal-immunità huwa stabbilit ġimagħtejn wara t-tilqima bażika. tul ta 'żmien tal-immunità: it-tul tal-immunità huwa ta' tliet xhur. il-vaċċin huwa maħsub għall-użu fiż-żwiemel li għalihom ġie identifikat b'mod ċar riskju ta 'infezzjoni streptococcus equi, minħabba kuntatt ma' żwiemel minn żoni fejn dan il-patoġenu hu magħruf li hu preżenti, e. stalel ma 'żwiemel li jivvjaġġaw għal wirjiet jew kompetizzjonijiet f'dawn iż-żoni, jew stalel li jakkwistaw jew ikollhom żwiemel tal-livery minn dawk iż-żoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - debridament - preparazzjonijiet għat-trattament ta 'feriti u ulċeri - nexobrid huwa indikat għat-tneħħija ta 'eschar f'adulti b'ħruq termali parzjali u ta' ħxuna sħiħa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meninġite, meningokokkali - vaċċini - nimenrix huwa indikat għall-immunizzazzjoni attiva ta 'individwi mill-età ta' 6 ġimgħat kontra mard invażiv meningokokkali kkawżat minn neisseria meningitidis grupp a, c, w-135, u y.